Form D · Pharmaceuticals
Synapsin Pharmaceuticals, Inc.
Columbia, SC · CIK 0001679593
Offering snapshot reported Jul 20, 2016 · SEC filing
- Reported sold
- $375K Offering amount: $3.75M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Jul 5, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 20, 2016 | Initial | $375,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-267417
Source: Form D, filed Jul 20, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Dorsey Denis | Director, Executive |
| Mark Kindy | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1225 Laurel Street Suite 213
Columbia, SC, 29201
Columbia, SC, 29201